معرفی
Dr. Sameer Parpia is an Associate Professor and Biostatistician at McMaster University's Faculty of Health Sciences, holding dual appointments in the Department of Oncology and the Department of Health Research Methods, Evidence, & Impact. He serves as a faculty biostatistician with the Ontario Clinical Oncology Group (OCOG), Lead of the Collaborative Unit Biostatistics and Evidence (CUBE), and Director of the Canadian Network for Statistical Training in Trials (CANSTAT). His academic leadership spans clinical trial methodology, biostatistics education, and research coordination across multiple national initiatives.
Dr. Parpia earned his B.Sc. from McMaster University, M.Sc. from Western University, and Ph.D. from McMaster University, establishing a strong foundation in statistical methodology and clinical research. His educational background directly supports his current roles in advancing clinical trial science and biostatistical training.
His research focuses on the design, conduct, and analysis of randomized clinical trials, with particular expertise in oncology, thrombosis diagnostics, radiotherapy optimization, and diagnostic algorithm development. Recent work demonstrates significant contributions to pulmonary embolism risk stratification, breast cancer treatment de-escalation, and venous thromboembolism management. His methodological innovations include developing and validating clinical prediction tools like the ToDay algorithm for deep vein thrombosis diagnosis and advancing the GRADE framework for evidence assessment.
Analysis of his 15 most recent publications reveals a strong emphasis on diagnostic accuracy studies (27%), clinical trial methodology (33%), and thrombosis/oncology applications (40%), with increasing focus on surgical outcomes research and evidence synthesis frameworks. His work consistently bridges statistical methodology with high-impact clinical applications across multiple specialties.
Dr. Parpia has secured substantial research funding including over $2.5 million in federal funding to address clinical trial biostatistician shortages through CANSTAT and contributed to $61 million in CIHR-funded projects at McMaster. His leadership in the LUSTRE randomized trial (comparing stereotactic vs. hypofractionated radiotherapy for lung cancer) and the PE-TRACT trial (evaluating catheter-directed therapy for pulmonary embolism) demonstrates his capacity to lead large-scale multicenter studies.
As an educator, he mentors students in the Health Research Methodology Program and directs CANSTAT's national training platform for clinical trial biostatisticians. His CUBE unit provides critical biostatistical support for OCOG's academic clinical trial coordination activities. Current projects include the PEREGRINE surgical trial for renal hyperparathyroidism and the ROSALIE study investigating radiotherapy omission in breast cancer.
